BFM
PDLI

Boston Financial Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Boston Financial Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,953
Closed -$38K – 270
2016
Q2 		$38K Hold
11,953
– – ﹤0.01% 247
2016
Q1 		$40K Hold
11,953
– – 0.01% 173
2015
Q4 		$42K Buy
+11,953
New +$50K 0.01% 181

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boston Financial Management's PDLI Position: Q3 2016 in Review

Boston Financial Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 11,953 shares — an estimated $38K sold.

Boston Financial Management first reported a position in PDLI in Q4 2015 and held it in 3 quarters. The position peaked at $42K in Q4 2015. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Boston Financial Management reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Boston Financial Management sold 11,953 PDL BioPharma, Inc. shares in Q3 2016, an estimated $38K.
  • Boston Financial Management first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 3 quarters.
  • Boston Financial Management's PDL BioPharma, Inc. position peaked at $42K in Q4 2015.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Boston Financial Management's 13F filing for Q3 2016, filed 4 Nov 2016.